Immunohistochemical and molecular cytogenetic evaluation of potential targets for tyrosine kinase inhibitors in Langerhans cell histiocytosis.

[1]  J. Blay.  A decade of tyrosine kinase inhibitor therapy: Historical and current perspectives on targeted therapy for GIST. , 2011, Cancer treatment reviews.

[2]  A. Angelucci,et al.  Cancer multitarget pharmacology in prostate tumors: tyrosine kinase inhibitors and beyond. , 2011, Current medicinal chemistry.

[3]  H. Ghofrani,et al.  Targeting non-malignant disorders with tyrosine kinase inhibitors , 2010, Nature Reviews Drug Discovery.

[4]  R. Egeler,et al.  Langerhans cell histiocytosis: Current concepts and treatments. , 2010, Cancer treatment reviews.

[5]  M. Yamakawa,et al.  Differential immunophenotypic analysis of dendritic cell tumours , 2010, Journal of Clinical Pathology.

[6]  C. Lome-Maldonado,et al.  Gastrointestinal Langerhans cell histiocytosis responding to cladribine and imatinib mesylate , 2010 .

[7]  J. Gotlib.  Eosinophilic myeloid disorders: new classification and novel therapeutic strategies , 2010, Current opinion in hematology.

[8]  W. Sanger,et al.  An increased frequency of 13q deletions detected by fluorescence in situ hybridization and its impact on survival in children and adolescents with Burkitt lymphoma: results from the Children’s Oncology Group study CCG‐5961 , 2010, British journal of haematology.

[9]  A. Tefferi,et al.  Hypereosinophilic syndrome and clonal eosinophilia: point-of-care diagnostic algorithm and treatment update. , 2010, Mayo Clinic proceedings.

[10]  H. Kurzen,et al.  Langerhans cell histiocytosis: treatment failure with imatinib. , 2009, Archives of dermatology.

[11]  J. Piette,et al.  Imatinib mesylate for platelet-derived growth factor receptor-beta-positive Erdheim-Chester histiocytosis. , 2008, Blood.

[12]  P. Chu,et al.  Immunohistochemical Expression of Langerin in Langerhans Cell Histiocytosis and Non-Langerhans Cell Histiocytic Disorders , 2008, The American journal of surgical pathology.

[13]  M. Rondoni,et al.  Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. , 2007, Blood.

[14]  J. Utikal,et al.  Imatinib as a treatment option for systemic non-Langerhans cell histiocytoses. , 2007, Archives of dermatology.

[15]  E. Scholar,et al.  Role of Tyrosine Kinase Inhibitors in Cancer Therapy , 2005, Journal of Pharmacology and Experimental Therapeutics.

[16]  Robert E. Brown.  Brief communication: morphoproteomic analysis of osteolytic Langerhans cell histiocytosis with therapeutic implications. , 2005, Annals of clinical and laboratory science.

[17]  R. Jaffe,et al.  Langerin (CD207) Staining in Normal Pediatric Tissues, Reactive Lymph Nodes, and Childhood Histiocytic Disorders , 2004, Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society.

[18]  L. Insabato,et al.  Imatinib mesylate for cerebral Langerhans'-cell histiocytosis. , 2004, The New England journal of medicine.

[19]  Peter Marynen,et al.  A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. , 2003, The New England journal of medicine.

[20]  G. Pinkus,et al.  Langerhans cell histiocytosis immunohistochemical expression of fascin, a dendritic cell marker. , 2002, American journal of clinical pathology.

[21]  R. Warnke,et al.  Tumours of histiocytes and accessory dendritic cells: an immunohistochemical approach to classification from the International Lymphoma Study Group based on 61 cases , 2002, Histopathology.

[22]  T. Colby,et al.  Pulmonary Langerhans' Cell Histiocytosis: Molecular Analysis of Clonality , 2001, The American journal of surgical pathology.

[23]  A. Kazlauskas,et al.  Disruption of Gap Junctional Communication by the Platelet-derived Growth Factor Is Mediated via Multiple Signaling Pathways* , 1999, The Journal of Biological Chemistry.

[24]  R. Arceci,et al.  Controversies and new approaches to treatment of Langerhans cell histiocytosis. , 1998, Hematology/oncology clinics of North America.

[25]  P. Gaulard,et al.  Langerhans' cell histiocytosis. Definitive diagnosis with the use of monoclonal antibody O10 on routinely paraffin-embedded samples. , 1995, The American journal of surgical pathology.

[26]  G. Cooper,et al.  Requirement for phosphatidylinositol-3 kinase in the prevention of apoptosis by nerve growth factor. , 1995, Science.

[27]  D. Gilliland,et al.  Langerhans'-cell histiocytosis (histiocytosis X)--a clonal proliferative disease. , 1994, The New England journal of medicine.

[28]  L. Buluwela,et al.  Clonal proliferation of Langerhans cells in Langerhans cell histiocytosis , 1994, The Lancet.

[29]  L. Boumsell,et al.  Immunohistochemical detection of cd1a antigen in formalin‐fixed and paraffin‐embedded tissue sections with monoclonal antibody 010 , 1993, The Journal of pathology.

[30]  R. Ross,et al.  The platelet-derived growth factor , 1978, Cell.

[31]  M. Staufenbiel,et al.  Amyloid beta-protein and apolipoprotein E co-localise within perivascular drainage channels in wild-type and APP-transgenic mice , 2006 .